IP Library Granted Patent US 10,265,000
Granted Patent B2
US 10,265,000 · App. 15/668,541 · Granted Apr 23, 2019

Low oxygen in vivo analyte sensor

Inventors: Mark C. Shults (Madison, WI); Rathbun K. Rhodes (Madison, WI); Stuart J. Updike (Madison, WI); James H. Brauker (Addison, MI)
Assignee: DexCom, Inc.
A61B5/14532A61B5/0002A61B5/0031A61B5/145A61B5/1495A61B5/14503A61B5/14865A61B5/150022A61B5/6846
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,265,000
App. No.
15/668,541
Granted
Apr 23, 2019
Kind
B2
Abstract

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous and subcutaneous measurement of glucose in a host.

Claims (18)

1. An implantable glucose sensor system comprising:

a glucose sensor comprising:

an implantable body comprising an electrode configured to measure a glucose level in a host; and

a membrane disposed over the electrode, wherein the membrane comprises:

a first layer configured to limit transport of glucose to the electrode;

a second layer comprising an enzyme to catalyze a reaction of glucose and oxygen as a co-reactant, wherein the enzyme is configured to use oxygen from a biological fluid surrounding the membrane to catalyze the reaction; and

a third layer configured to reduce a flux of an interferent, wherein the third layer comprises polymers having ionic groups; and

a sensor electronics unit operably connected to the electrode and configured to measure a current produced by the electrode;

wherein the the glucose sensor is configured to measure glucose concentration with substantial linearity at glucose concentrations of up to 400 mg/dL at an oxygen concentration of 0.6 mg/L.

2. The implantable glucose sensor system of claim 1 , wherein the sensor electronics unit is configured to directly measure the current produced by the electrode.

3. The implantable glucose sensor system of claim 1 , wherein the glucose sensor further comprises a biointerface layer configured to support tissue ingrowth.

4. The implantable glucose sensor system of claim 1 , further comprising an analog-to-digital converter configured to translate the current into a digital signal.

5. The implantable glucose sensor system of claim 1 , wherein the electrode comprises an exposed electroactive working electrode surface with a surface area of from about 0.00002 in 2 to about 0.0079 in 2 .

6. The implantable glucose sensor system of claim 1 , wherein the first layer is configured to have a permeability ratio of at least about 50:1 of oxygen to glucose.

7. The implantable glucose sensor system of claim 1 , wherein the first layer is configured to have a permeability ratio of at least about 200:1 of oxygen to glucose.

8. The implantable glucose sensor system of claim 1 , wherein the sensor system is configured to have, in operation, a sensitivity of from about 1 pA/mg/dL to about 100 pA/mg/dL.

9. The implantable glucose sensor system of claim 1 , wherein the sensor system is configured to have, in operation, a sensitivity of from about 5 pA/mg/dL to about 25 pA/mg/dL.

10. The implantable glucose sensor system of claim 1 , wherein the sensor system is configured to have, in operation, a sensitivity of from about 3.5 to about 7.5 pA/mg/dL.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2018
From: SHULTS, MARK; RHODES, RATHBUN K.; UPDIKE, STUART J.; BRAUKER, JAMES H.
To: DEXCOM, INC.
Reel/Frame 044691/0982 →
Continuity (4)
Continuation 14842276 · Sep 1, 2015
Continuation 13031063 · Feb 18, 2011
Continuation 11333837 · Jan 17, 2006
Related Publication 20170325726A1 · Nov 16, 2017